Details of Disease

General Information of Disease (ID: DIS0QADF)

Disease Name Graft-versus-host disease
Synonyms
graft-versus-host diseases; graft-versus-host disease, susceptibility to; homologous wasting disease; disease, homologous wasting; graft-VS-host diseases; disease, runt; graft-versus-host disease, resistance to; diseases, graft-vs-host; GVH; graft-vs-host disease; runt disease; diseases, graft-versus-host; graft-versus-host-disease; graft vs host disease; disease, graft-versus-host; GVHD; disease, graft-vs-host; graft-versus-host disease; graft versus host disease; graft vs. host disease
Disease Class 4B24: Graft-versus-host disease
Definition
An immune system disorder that occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen.
Disease Hierarchy
DISN1N0F: Stem cell engraftment
DISAEGPH: Immune system disorder
DIS0QADF: Graft-versus-host disease
ICD Code
ICD-11
ICD-11: 4B24
ICD-9
ICD-9: 279.5
Expand ICD-11
'4B24
Expand ICD-9
279.5
Disease Identifiers
MONDO ID
MONDO_0013730
MESH ID
D006086
UMLS CUI
C0018133
MedGen ID
9082
Orphanet ID
39812
SNOMED CT ID
234646005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 6 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Belumosudil DM548TK Approved NA [1]
Ciclosporin DMAZJFX Approved NA [2]
Everolimus DM8X2EH Approved Small molecular drug [3]
Muromonab-cd3 DM71NBK Approved NA [4]
Sirolimus DMGW1ID Approved Small molecular drug [5]
Tacrolimus DMZ7XNQ Approved Small molecular drug [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 19 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
TK-DLI DM26I8H Preregistration NA [7]
Anti-T-lymphocyte immune globulin DMAEBSO Phase 3 NA [8]
BB3 DMZ8AL8 Phase 3 Small molecular drug [8]
MultiStem DMOT705 Phase 3 NA [9]
NN8717 DM1PI9G Phase 3 NA [10]
Prochymal DMWTCWM Phase 3 NA [11]
Remestemcel-L DM02MRW Phase 3 Cell therapy [12]
T-Guard DMKHPA5 Phase 3 NA [13]
TZ101 DM5KVMP Phase 3 NA [8]
Visilizumab DMXYM1H Phase 3 Antibody [14]
Gavilimomab DMH7CSQ Phase 2/3 Antibody [15]
CaspaCIDe donor lymphocyte infusion DMEMYD7 Phase 2 NA [16]
F-652 DM9201K Phase 2 Recombinant protein [17]
RGI-2001 DM4AC2F Phase 2 NA [8]
TH-9402 DMH2KSG Phase 2 Small molecular drug [18]
AMG 592 DMBIT2F Phase 1/2 Fusion protein [19]
RG2077 DMMI258 Phase 1/2 NA [20]
TK-54 DMT44QW Phase 1/2 NA [21]
NJA-730 DM4I02O Phase 1 Antisense oligonucleotide [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 Drug(s)
This Disease is Treated as An Indication in 2 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
FR-901483 DMLF5S9 Discontinued in Phase 1 NA [23]
ICM-3 DMDBICR Terminated Antibody [24]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
HE-33 DMU7IZY Investigative NA [25]
IB-08C175 DMFOMPL Investigative NA [25]
ImmuStem DMAFZN5 Investigative NA [25]
LT-1945 DMON4EW Investigative NA [25]
R-524 DMHLUZN Investigative NA [25]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 76 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CYP26A1 TTD7Q0R Limited Biomarker [26]
IL3RA TTENHJ0 Limited Biomarker [27]
ITK TT3C80U Limited Biomarker [28]
KCNJ5 TTEO25X Limited Genetic Variation [29]
KIR2DL2 TTU0P73 Limited Biomarker [30]
KIR2DS2 TTV3CFI Limited Biomarker [30]
KLRC1 TTC4IMS Limited Biomarker [30]
LY9 TTZCL1U Limited Biomarker [31]
MLANA TT362RB Limited Biomarker [32]
MTHFR TTQWOU1 Limited Genetic Variation [33]
PRKCQ TT1MS7X Limited Biomarker [28]
S1PR5 TTDZCKV Limited Biomarker [34]
TNFRSF17 TTZ3P4W Limited Biomarker [35]
CCR9 TTIPS8B moderate Biomarker [36]
CD1A TTBGTFN moderate Biomarker [37]
CD4 TTN2JFW moderate Biomarker [38]
CTSH TT3G406 moderate Altered Expression [39]
DOT1L TTSZ8T1 moderate Altered Expression [40]
F2RL2 TTVSEBF moderate Biomarker [41]
FFAR2 TT0FYAN moderate Biomarker [42]
GSTA1 TT4P8DE moderate Genetic Variation [43]
ITGB7 TTLT9XQ moderate Biomarker [44]
LILRB4 TTREOKA moderate Biomarker [45]
MADCAM1 TTBD6I7 moderate Altered Expression [44]
MASP2 TTR01E9 moderate Genetic Variation [46]
PIM2 TT69J2Z moderate Biomarker [47]
PTAFR TTQL5VC moderate Biomarker [48]
TIGIT TTWNL74 moderate Biomarker [49]
TLR6 TTWRI8V moderate Biomarker [50]
BCL2A1 TTGT9C7 Strong Biomarker [51]
C5AR1 TTHXFA1 Strong Biomarker [52]
CD34 TTZAVYN Strong Genetic Variation [53]
CD3E TTZAT79 Strong Biomarker [54]
CD80 TT89Z17 Strong Altered Expression [55]
CHM TTOA18V Strong Biomarker [56]
CTLA4 TTI2S1D Strong Biomarker [57]
DDX58 TTVB0O3 Strong Biomarker [58]
EBI3 TTJF68X Strong Biomarker [59]
FASLG TTO7014 Strong Biomarker [60]
FGF7 TTFY134 Strong Biomarker [61]
HLA-A TTHONFT Strong Biomarker [62]
HSPA8 TTMQL3K Strong Biomarker [63]
IFNG TT93WF5 Strong Biomarker [64]
IL10 TTT0Q1F Strong Biomarker [65]
IL10RB TTJTRMK Strong Genetic Variation [66]
IL17A TTG0MT6 Strong Altered Expression [67]
IL21 TT9QEJ6 Strong Biomarker [68]
IL22 TTLDX4N Strong Altered Expression [69]
IL2RA TT10Y9E Strong Biomarker [70]
IL7 TT8FRMO Strong Altered Expression [71]
IL7R TTAWI51 Strong Genetic Variation [72]
IL9 TT0JTFD Strong Biomarker [73]
JAK3 TTT7PJU Strong Biomarker [74]
KIR2DL3 TTEX3SI Strong Biomarker [75]
KIR3DL2 TTQH3N0 Strong Altered Expression [76]
LTB4R TTN53ZF Strong Biomarker [77]
MAP3K7 TTJQT60 Strong Biomarker [55]
NCAM1 TTVXPHT Strong Biomarker [78]
NOD2 TTYPUHA Strong Genetic Variation [79]
P2RX7 TT473XN Strong Altered Expression [80]
SCT TTOBVIN Strong Genetic Variation [81]
TLR5 TTCXP8J Strong Biomarker [82]
TNFRSF25 TTDV6BQ Strong Altered Expression [83]
TNFSF14 TTKVENM Strong Biomarker [84]
TNFSF15 TTEST6I Strong Biomarker [83]
CD19 TTW640A Definitive Biomarker [85]
CD28 TTQ13FT Definitive Biomarker [86]
CD52 TTQT5S9 Definitive Biomarker [87]
FLT3 TTGJCWZ Definitive Biomarker [71]
GZMB TTKEPHX Definitive Biomarker [88]
ICOS TTE5VP6 Definitive Biomarker [68]
IL15 TTJFA35 Definitive Biomarker [89]
JAK1 TT6DM01 Definitive Biomarker [90]
MYD88 TTB6Q2O Definitive Biomarker [91]
REG3A TTL4H8N Definitive Altered Expression [92]
THBD TTAPV67 Definitive Biomarker [93]
------------------------------------------------------------------------------------
⏷ Show the Full List of 76 DTT(s)
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ALDH1A2 DEKN1H4 Limited Biomarker [26]
NDUFS3 DE741FI Limited Genetic Variation [94]
------------------------------------------------------------------------------------
This Disease Is Related to 77 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BAMBI OTCEJ8W5 Limited Biomarker [95]
BTNL2 OTTTEMZA Limited Biomarker [96]
CIR1 OTKP5JKH Limited Genetic Variation [29]
CLDN15 OT9K0KI7 Limited Altered Expression [97]
CLDN2 OTRF3D6Y Limited Altered Expression [97]
EMD OTR8ZANE Limited Biomarker [98]
FLG OTE9QDV6 Limited Altered Expression [99]
IFNL2 OT4BMJF7 Limited Biomarker [100]
ITFG1 OTX0PCR3 Limited Biomarker [101]
KLRD1 OTMYLOV4 Limited Biomarker [30]
MBD5 OTFHT4MO Limited Biomarker [102]
METTL8 OT7E09Y4 Limited Biomarker [101]
MTFMT OT1OIVJL Limited Biomarker [103]
NLRP6 OTEREN4W Limited Biomarker [104]
PI3 OT47MTC3 Limited Biomarker [105]
RBM19 OT3Q6UIM Limited Biomarker [102]
RTL1 OTOT33IM Limited Biomarker [32]
SLAMF1 OTBTT3ZQ Limited Biomarker [106]
SPRR1B OTXNW3P6 Limited Biomarker [107]
TIPRL OTS2FZ8O Limited Biomarker [101]
ADGRL4 OTN1GAG7 moderate Biomarker [108]
ATG10 OTVRPC5X moderate Biomarker [109]
ATP2C1 OTQN51T3 moderate Biomarker [110]
BANK1 OTXAAA11 moderate Genetic Variation [111]
BATF OT9VSD2D moderate Biomarker [112]
CCL24 OT9LGHV0 moderate Biomarker [113]
CD300C OT4BSR7D moderate Biomarker [114]
CERS6 OTOP4GV1 moderate Biomarker [115]
CFHR1 OT72R16T moderate Biomarker [116]
CFHR3 OTYL8SDO moderate Biomarker [116]
FUT2 OTLXM6WI moderate Genetic Variation [117]
FXYD5 OT81DIOD moderate Genetic Variation [118]
GLCCI1 OTU0R1CU moderate Biomarker [119]
GNLY OTZJKA8C moderate Biomarker [120]
GZMA OT43R33L moderate Biomarker [121]
IKZF1 OTCW1FKL moderate Altered Expression [122]
ITIH4 OT460OO1 moderate Biomarker [123]
IVL OT4VPNGY moderate Altered Expression [124]
KDM5D OTEKG0KD moderate Biomarker [125]
KLRC2 OTT4N86S moderate Biomarker [126]
KRT15 OTS6WLF7 moderate Biomarker [127]
MARCHF7 OTG9SF10 moderate Altered Expression [128]
MYO1G OTOCFS3Q moderate Biomarker [129]
PARD3 OTH5BPLO moderate Biomarker [41]
PPP1R42 OTN1HRBN moderate Biomarker [130]
RTN3 OTGZ51QF moderate Biomarker [131]
SAFB OTGRV2LW moderate Biomarker [131]
SUFU OT0IRYG1 moderate Genetic Variation [132]
TLR10 OTQ1KVJO moderate Biomarker [50]
AP5M1 OTDLWEBL Strong Biomarker [133]
ARHGAP45 OTL86FEQ Strong Biomarker [134]
ARR3 OTRZ00CH Strong Biomarker [135]
ATN1 OTNZFLKY Strong Biomarker [136]
CABIN1 OT4G5CIK Strong Genetic Variation [137]
CCL8 OTCTWYN8 Strong Biomarker [138]
DDX3Y OTKL1FNX Strong Biomarker [139]
DHX15 OT4F98TK Strong Biomarker [140]
EBAG9 OTTQLQCP Strong Biomarker [141]
HLA-C OTV38BUJ Strong Biomarker [142]
HLA-DRB3 OT5PM9N7 Strong Biomarker [143]
HLA-E OTX1CTFB Strong Genetic Variation [144]
HSPA1A OTKGIE76 Strong ModifyingMutation [145]
HSPA1L OTC2V1K6 Strong Altered Expression [146]
IL2RG OTRZ3OMY Strong Genetic Variation [147]
ISG20 OTCWRJJW Strong Biomarker [70]
MAVS OTTQ0J64 Strong Biomarker [58]
MLC1 OTCNZLSP Strong Biomarker [148]
MTX1 OTLSDNZO Strong Genetic Variation [149]
NOG OTGRHHPG Strong Biomarker [32]
NT5C1A OTS7UF36 Strong Biomarker [150]
P2RX5 OTLBR20R Strong Biomarker [151]
PLAAT4 OTI66SAJ Strong Biomarker [58]
RAG2 OTG9UYTW Strong Biomarker [152]
ROBO3 OTPVG40S Strong Biomarker [58]
TRIM13 OTQIUACB Strong Biomarker [135]
TSSK1B OTRATM7R Strong Biomarker [153]
RBM45 OTWTHD77 Definitive Genetic Variation [154]
------------------------------------------------------------------------------------
⏷ Show the Full List of 77 DOT(s)

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214783.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Everolimus FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6889).
5 Sirolimus FDA Label
6 Tacrolimus FDA Label
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023073)
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 ClinicalTrials.gov (NCT02277613) A Phase 2 Trial of AMI MultiStem Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction. U.S. National Institutes of Health.
10 Clinical pipeline report, company report or official report of Novo Nordisk A/S.
11 ClinicalTrials.gov (NCT00482092) Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease. U.S. National Institutes of Health.
12 ClinicalTrials.gov (NCT02652130) Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD. U.S. National Institutes of Health.
13 ClinicalTrials.gov (NCT04934670) A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients With Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (BMT CTN 2002). U.S.National Institutes of Health.
14 ClinicalTrials.gov (NCT00502294) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT00035880) Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease. U.S. National Institutes of Health.
16 Clinical pipeline report, company report or official report of Bellicum Pharmaceuticals Inc.
17 ClinicalTrials.gov (NCT02406651) A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT). U.S.National Institutes of Health.
18 ClinicalTrials.gov (NCT02519816) Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD.
19 ClinicalTrials.gov (NCT03422627) A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Efavaleukin Alfa in Adult Subjects With Steroid Refractory Chronic Graft Versus Host Disease. U.S.National Institutes of Health.
20 ClinicalTrials.gov (NCT00094380) Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077). U.S. National Institutes of Health.
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024880)
22 Clinical pipeline report, company report or official report of NapaJen Pharma.
23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006435)
24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007018)
25 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
26 Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.J Immunol. 2019 May 1;202(9):2795-2805. doi: 10.4049/jimmunol.1800899. Epub 2019 Mar 18.
27 Histologic analysis has a prognostical value in colorectal biopsies assessed for suspicion of graft-versus-host disease.Virchows Arch. 2018 Feb;472(2):213-220. doi: 10.1007/s00428-017-2272-2. Epub 2017 Nov 22.
28 Cymerus?iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease.Stem Cell Res. 2019 Mar;35:101401. doi: 10.1016/j.scr.2019.101401. Epub 2019 Feb 1.
29 Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.J Clin Oncol. 2019 Feb 10;37(5):375-385. doi: 10.1200/JCO.2018.79.2184. Epub 2018 Nov 7.
30 Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation.Hematology. 2003 Feb;8(1):19-26. doi: 10.1080/1024533031000072045.
31 The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease.Front Immunol. 2019 Apr 17;10:831. doi: 10.3389/fimmu.2019.00831. eCollection 2019.
32 Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.Cell Mol Immunol. 2018 Nov;15(11):953-962. doi: 10.1038/cmi.2017.106. Epub 2017 Nov 20.
33 Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.Leukemia. 2009 Mar;23(3):545-56. doi: 10.1038/leu.2008.323. Epub 2008 Nov 13.
34 S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.Hematol Oncol. 2020 Feb;38(1):89-102. doi: 10.1002/hon.2669. Epub 2019 Nov 26.
35 Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
36 Genetic polymorphisms in the cytokine and chemokine system: their possible importance in allogeneic stem cell transplantation.Curr Top Microbiol Immunol. 2010;341:83-96. doi: 10.1007/82_2010_22.
37 Impact of mismatching CD1a, a dimorphic antigen-presenting molecule, on graft-versus-host disease after hematopoietic stem cell transplantation.Transplantation. 2006 Nov 27;82(10):1374-6. doi: 10.1097/01.tp.0000235604.44449.50.
38 Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.Blood. 2005 Oct 15;106(8):2903-11. doi: 10.1182/blood-2005-03-1257. Epub 2005 Jun 21.
39 The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303.Br J Haematol. 2006 Aug;134(4):406-16. doi: 10.1111/j.1365-2141.2006.06205.x. Epub 2006 Jul 4.
40 DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.Nat Commun. 2018 May 15;9(1):1915. doi: 10.1038/s41467-018-04262-0.
41 Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.Nat Commun. 2017 Aug 21;8(1):311. doi: 10.1038/s41467-017-00169-4.
42 Microbial metabolite sensor GPR43 controls severity of experimental GVHD.Nat Commun. 2018 Sep 10;9(1):3674. doi: 10.1038/s41467-018-06048-w.
43 Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.Clin Transplant. 2007 Mar-Apr;21(2):207-13. doi: 10.1111/j.1399-0012.2006.00624.x.
44 Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-7 during Acute Graft-versus-Host Disease of the Liver.Biol Blood Marrow Transplant. 2015 Dec;21(12):2069-2078. doi: 10.1016/j.bbmt.2015.08.038. Epub 2015 Sep 5.
45 Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc.Hum Immunol. 2009 Sep;70(9):663-9. doi: 10.1016/j.humimm.2009.06.001. Epub 2009 Jun 6.
46 Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation.Exp Hematol. 2006 Oct;34(10):1435-41. doi: 10.1016/j.exphem.2006.06.005.
47 PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.J Clin Invest. 2018 Jul 2;128(7):2787-2801. doi: 10.1172/JCI95407. Epub 2018 May 21.
48 Platelet-activating factor receptor plays a role in the pathogenesis of graft-versus-host disease by regulating leukocyte recruitment, tissue injury, and lethality.J Leukoc Biol. 2012 Apr;91(4):629-39. doi: 10.1189/jlb.1111561. Epub 2012 Feb 1.
49 TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):3085-3098. doi: 10.1016/j.bbadis.2018.06.022. Epub 2018 Jun 28.
50 Toll-like receptor gene polymorphisms confer susceptibility to graft-versus-host disease in allogenic hematopoietic stem cell transplantation.Scand J Immunol. 2012 Sep;76(3):336-41. doi: 10.1111/j.1365-3083.2012.02737.x.
51 Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.Blood. 2005 Dec 1;106(12):3955-7. doi: 10.1182/blood-2004-09-3749. Epub 2005 Aug 11.
52 Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells.JCI Insight. 2018 Dec 20;3(24):e121697. doi: 10.1172/jci.insight.121697.
53 Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCR(+)/CD19(+)-depleted grafts.Blood Adv. 2018 Feb 13;2(3):263-270. doi: 10.1182/bloodadvances.2017012005.
54 A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.Blood Adv. 2018 Mar 13;2(5):517-528. doi: 10.1182/bloodadvances.2017012823.
55 Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.J Clin Invest. 2020 Mar 2;130(3):1315-1329. doi: 10.1172/JCI130272.
56 MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease.Mucosal Immunol. 2016 May;9(3):730-43. doi: 10.1038/mi.2015.96. Epub 2015 Oct 7.
57 The emerging role of immune checkpoint based approaches in AML and MDS.Leuk Lymphoma. 2018 Apr;59(4):790-802. doi: 10.1080/10428194.2017.1344905. Epub 2017 Jul 6.
58 Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells.Sci Rep. 2019 Oct 18;9(1):14955. doi: 10.1038/s41598-019-51431-2.
59 Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).BMC Cancer. 2018 Nov 19;18(1):1132. doi: 10.1186/s12885-018-5045-7.
60 Early detection of apoptosis and fas ligand expression in hepatic graft-versus-host disease after rat small bowel transplantation.J Surg Res. 1999 Sep;86(1):136-44. doi: 10.1006/jsre.1999.5706.
61 Cytotoxic Effects of Rabbit Anti-thymocyte Globulin Preparations on Primary Human Thymic Epithelial Cells.Transplantation. 2019 Nov;103(11):2234-2244. doi: 10.1097/TP.0000000000002799.
62 Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.Blood Adv. 2019 Nov 26;3(22):3522-3538. doi: 10.1182/bloodadvances.2019000411.
63 Expression of 70-kDa heat-shock protein during acute graft-versus-host disease.Clin Immunol Immunopathol. 1998 Mar;86(3):252-8. doi: 10.1006/clin.1997.4473.
64 Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.Leukemia. 2018 Nov;32(11):2483-2494. doi: 10.1038/s41375-018-0123-z. Epub 2018 Apr 2.
65 Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.JCI Insight. 2019 Mar 7;4(5):e122014. doi: 10.1172/jci.insight.122014. eCollection 2019 Mar 7.
66 IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation.Transplantation. 2009 Mar 15;87(5):704-10. doi: 10.1097/TP.0b013e318195c474.
67 Increased splenic human CD4(+):CD8(+) T cell ratios, serum human interferon- and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized mice.Transpl Immunol. 2019 Jun;54:38-46. doi: 10.1016/j.trim.2019.02.003. Epub 2019 Feb 8.
68 T follicular helper-like cells contribute to skin fibrosis.Sci Transl Med. 2018 Mar 7;10(431):eaaf5307. doi: 10.1126/scitranslmed.aaf5307.
69 Donor T-cell-derived interleukin-22 promotes thymus regeneration and alleviates chronic graft-versus-host disease in murine allogeneic hematopoietic cell transplant.Int Immunopharmacol. 2019 Feb;67:194-201. doi: 10.1016/j.intimp.2018.12.023. Epub 2018 Dec 14.
70 Very Low Numbers of CD4(+)FoxP3(+)Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.Biol Blood Marrow Transplant. 2018 Sep;24(9):1788-1794. doi: 10.1016/j.bbmt.2018.04.026. Epub 2018 May 8.
71 IL-7 Is the Limiting Homeostatic Factor that Constrains Homeostatic Proliferation of CD8(+) T Cells after Allogeneic Stem Cell Transplantation and Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2019 Apr;25(4):648-655. doi: 10.1016/j.bbmt.2018.12.066. Epub 2018 Dec 19.
72 Donor Genotype in the Interleukin-7 Receptor -Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2018 Feb 2;9:109. doi: 10.3389/fimmu.2018.00109. eCollection 2018.
73 Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.J Exp Med. 2017 Dec 4;214(12):3577-3596. doi: 10.1084/jem.20170041. Epub 2017 Oct 16.
74 Graft versus host disease and microchimerism in a JAK3 deficient patient.Allergy Asthma Clin Immunol. 2019 Aug 22;15:47. doi: 10.1186/s13223-019-0361-2. eCollection 2019.
75 Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.J Immunol. 2019 Apr 1;202(7):2141-2152. doi: 10.4049/jimmunol.1801489. Epub 2019 Feb 20.
76 Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.Ann Hematol. 2018 Jun;97(6):1027-1039. doi: 10.1007/s00277-018-3274-0. Epub 2018 Mar 16.
77 BLT-humanized C57BL/6 Rag2-/-c-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.Blood. 2013 Dec 12;122(25):4013-20. doi: 10.1182/blood-2013-06-506949. Epub 2013 Sep 10.
78 Unusual expansion of CD3+CD56+ natural killer T-like cells in peripheral blood after anticytokine treatment for graft-versus-host disease: A case report.Medicine (Baltimore). 2018 Sep;97(38):e12429. doi: 10.1097/MD.0000000000012429.
79 Nod2: The intestinal gate keeper.PLoS Pathog. 2017 Mar 2;13(3):e1006177. doi: 10.1371/journal.ppat.1006177. eCollection 2017 Mar.
80 Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.Purinergic Signal. 2019 Jun;15(2):177-192. doi: 10.1007/s11302-019-09651-8. Epub 2019 Apr 18.
81 Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.Ann Hematol. 2019 May;98(5):1267-1277. doi: 10.1007/s00277-019-03636-8. Epub 2019 Feb 12.
82 Targeting T Cell Activation and Lupus Autoimmune Phenotypes by Inhibiting Glucose Transporters.Front Immunol. 2019 Apr 17;10:833. doi: 10.3389/fimmu.2019.00833. eCollection 2019.
83 Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.Front Immunol. 2019 Jul 17;10:1624. doi: 10.3389/fimmu.2019.01624. eCollection 2019.
84 LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):289-96. doi: 10.1016/s1359-6101(03)00031-5.
85 Mismatched related vs matched unrelated donors in TCR/CD19-depleted HSCT for primary immunodeficiencies.Blood. 2019 Nov 14;134(20):1755-1763. doi: 10.1182/blood.2019001757.
86 CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.J Clin Invest. 2018 Aug 31;128(9):3991-4007. doi: 10.1172/JCI98793. Epub 2018 Aug 13.
87 Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.Transpl Immunol. 2019 Dec;57:101209. doi: 10.1016/j.trim.2019.06.001. Epub 2019 Jun 14.
88 Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect.Oncoimmunology. 2017 Nov 16;7(3):e1397247. doi: 10.1080/2162402X.2017.1397247. eCollection 2018.
89 GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.Blood. 2017 Feb 2;129(5):630-642. doi: 10.1182/blood-2016-08-734020. Epub 2016 Dec 7.
90 Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.Clin Pharmacol Drug Dev. 2020 Aug;9(6):677-688. doi: 10.1002/cpdd.758. Epub 2019 Dec 10.
91 Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation.Clin Exp Immunol. 2019 Jan;195(1):121-131. doi: 10.1111/cei.13215. Epub 2018 Oct 14.
92 ST2 and REG3 as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.Front Immunol. 2019 Oct 9;10:2338. doi: 10.3389/fimmu.2019.02338. eCollection 2019.
93 Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells.Blood. 2019 Aug 29;134(9):776-781. doi: 10.1182/blood.2019001259. Epub 2019 Jun 26.
94 Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.Cancer Cell Int. 2018 Apr 23;18:62. doi: 10.1186/s12935-018-0553-8. eCollection 2018.
95 Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.
96 In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.Cell Immunol. 2019 Jan;335:22-29. doi: 10.1016/j.cellimm.2018.10.008. Epub 2018 Oct 26.
97 Differential regulation of claudin-2 and claudin-15 expression in children and adults with malabsorptive disease.Lab Invest. 2020 Mar;100(3):483-490. doi: 10.1038/s41374-019-0324-8. Epub 2019 Oct 11.
98 Extracranial-Intracranial Bypass for Cerebral Vasculitis After Graft-Versus-Host Disease: Case Report and Review of the Literature.World Neurosurg. 2019 Mar;123:193-196. doi: 10.1016/j.wneu.2018.11.256. Epub 2018 Dec 18.
99 Increased regulatory T cells and eosinophils characterize atopic dermatitis-like graft-versus-host disease compared with lichen planus-like graft-versus-host disease.J Am Acad Dermatol. 2020 Sep;83(3):824-831. doi: 10.1016/j.jaad.2019.08.005. Epub 2019 Aug 9.
100 Regeneration After Radiation- and Immune-Mediated Tissue Injury Is Not Enhanced by Type III Interferon Signaling.Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):970-976. doi: 10.1016/j.ijrobp.2018.11.038. Epub 2018 Nov 29.
101 TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model.Nat Biotechnol. 2003 Mar;21(3):302-7. doi: 10.1038/nbt797. Epub 2003 Feb 24.
102 Eyelid metrics assessment in patients with chronic ocular graft versus-host disease.Ocul Surf. 2019 Jan;17(1):98-103. doi: 10.1016/j.jtos.2018.10.005. Epub 2018 Oct 12.
103 Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients.EBioMedicine. 2019 Jun;44:730-740. doi: 10.1016/j.ebiom.2019.03.070. Epub 2019 Mar 30.
104 Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition.Nat Microbiol. 2019 May;4(5):800-812. doi: 10.1038/s41564-019-0373-1. Epub 2019 Mar 11.
105 Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study.Clin Exp Dermatol. 2019 Mar;44(2):161-168. doi: 10.1111/ced.13678. Epub 2018 Jun 7.
106 CD150(high)Treg cells may attenuate graft versus host disease and intestinal cell apoptosis after hematopoietic stem cell transplantation.Am J Transl Res. 2019 Mar 15;11(3):1299-1310. eCollection 2019.
107 Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD.Ocul Surf. 2019 Apr;17(2):285-294. doi: 10.1016/j.jtos.2019.01.001. Epub 2019 Jan 8.
108 Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation.Immunogenetics. 2013 Jun;65(6):417-27. doi: 10.1007/s00251-013-0691-z. Epub 2013 Mar 9.
109 Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.Cancer. 2017 Aug 1;123(15):2881-2892. doi: 10.1002/cncr.30540. Epub 2017 Mar 16.
110 Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.Front Immunol. 2018 Aug 30;9:1943. doi: 10.3389/fimmu.2018.01943. eCollection 2018.
111 Genetic risk factors for sclerotic graft-versus-host disease.Blood. 2016 Sep 15;128(11):1516-24. doi: 10.1182/blood-2016-05-715342. Epub 2016 Jun 16.
112 BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.J Clin Invest. 2018 Mar 1;128(3):916-930. doi: 10.1172/JCI89242. Epub 2018 Jan 29.
113 Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2018 Oct;24(10):1971-1980. doi: 10.1016/j.bbmt.2018.05.029. Epub 2018 Jun 5.
114 A CD300c-Fc Fusion Protein Inhibits T Cell Immunity.Front Immunol. 2018 Nov 15;9:2657. doi: 10.3389/fimmu.2018.02657. eCollection 2018.
115 Ceramide synthesis regulates T cell activity and GVHD development.JCI Insight. 2017 May 18;2(10):e91701. doi: 10.1172/jci.insight.91701. eCollection 2017 May 18.
116 Copy number polymorphisms in new HapMap III and Singapore populations.J Hum Genet. 2011 Aug;56(8):552-60. doi: 10.1038/jhg.2011.54. Epub 2011 Jun 16.
117 A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2016 Mar;22(3):418-22. doi: 10.1016/j.bbmt.2015.11.017. Epub 2015 Nov 28.
118 Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.Bone Marrow Transplant. 2010 Mar;45(3):534-42. doi: 10.1038/bmt.2009.180. Epub 2009 Aug 10.
119 GLCCI1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2015 Jul;21(7):1246-50. doi: 10.1016/j.bbmt.2015.03.015. Epub 2015 Apr 3.
120 A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.J Allergy Clin Immunol. 2013 Sep;132(3):713-722.e11. doi: 10.1016/j.jaci.2013.04.036. Epub 2013 Jun 19.
121 Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease.PLoS One. 2015 Apr 30;10(4):e0124927. doi: 10.1371/journal.pone.0124927. eCollection 2015.
122 Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.Transpl Immunol. 2012 Dec;27(4):179-83. doi: 10.1016/j.trim.2012.07.003. Epub 2012 Aug 4.
123 Novel Concept of CD4-Mediated Activation of Regulatory T Cells for the Treatment of Graft-Versus-Host Disease.Front Immunol. 2017 Nov 8;8:1495. doi: 10.3389/fimmu.2017.01495. eCollection 2017.
124 Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules.Chin Med J (Engl). 2017 Jun 20;130(12):1459-1466. doi: 10.4103/0366-6999.207475.
125 Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.Blood. 2005 Apr 1;105(7):2973-8. doi: 10.1182/blood-2004-09-3660. Epub 2004 Dec 21.
126 The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.Int J Mol Sci. 2016 Oct 27;17(11):1797. doi: 10.3390/ijms17111797.
127 Graft-versus-host disease-related cytokine-driven apoptosis depends on p73 in cytokeratin 15-positive target cells.Biol Blood Marrow Transplant. 2012 Jun;18(6):841-51. doi: 10.1016/j.bbmt.2012.02.004. Epub 2012 Mar 30.
128 Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance.Int Immunopharmacol. 2006 Dec 20;6(13-14):1993-2001. doi: 10.1016/j.intimp.2006.09.015. Epub 2006 Oct 17.
129 Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive Tunisian recipients of HSCs.Immunol Invest. 2010;39(6):611-20. doi: 10.3109/08820131003775029.
130 Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.J Immunol. 2017 May 1;198(9):3746-3754. doi: 10.4049/jimmunol.1502399. Epub 2017 Mar 22.
131 Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial.J Cancer Res Clin Oncol. 2017 Aug;143(8):1613-1619. doi: 10.1007/s00432-017-2424-4. Epub 2017 Apr 19.
132 Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells.Sci Rep. 2015 Jun 11;5:11098. doi: 10.1038/srep11098.
133 Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.Biol Blood Marrow Transplant. 2019 Jul;25(7):1465-1471. doi: 10.1016/j.bbmt.2019.03.025. Epub 2019 Mar 27.
134 Does minor histocompatibility antigen HA-1 disparity affect the occurrence of graft-versus-host disease in tunisian recipients of hematopoietic stem cells?.Clinics (Sao Paulo). 2010;65(11):1099-103. doi: 10.1590/s1807-59322010001100007.
135 Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.Immunotherapy. 2019 Jan;11(1):37-44. doi: 10.2217/imt-2018-0089.
136 Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model.EBioMedicine. 2019 Mar;41:584-596. doi: 10.1016/j.ebiom.2019.02.001. Epub 2019 Feb 13.
137 Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.Biol Blood Marrow Transplant. 2020 Mar;26(3):519-528. doi: 10.1016/j.bbmt.2019.11.001. Epub 2019 Nov 9.
138 Upregulation of plasma CCL8 in mouse model of graft-vs-host disease.Exp Hematol. 2009 Apr;37(4):525-31. doi: 10.1016/j.exphem.2008.12.006.
139 The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.Blood. 2002 Apr 15;99(8):3027-32. doi: 10.1182/blood.v99.8.3027.
140 DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation.Bone Marrow Transplant. 2002 Oct;30(8):497-502. doi: 10.1038/sj.bmt.1703658.
141 The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract.J Hepatol. 2002 Jun;36(6):786-92. doi: 10.1016/s0168-8278(02)00066-1.
142 Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2020 Feb;26(2):230-241. doi: 10.1016/j.bbmt.2019.09.030. Epub 2019 Oct 2.
143 Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.Transplantation. 2017 Dec;101(12):2850-2854. doi: 10.1097/TP.0000000000001713.
144 The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.Iran J Allergy Asthma Immunol. 2012 Mar;11(1):15-21.
145 Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-host reaction in a rat skin explant model.Transplantation. 2008 Jun 27;85(12):1809-16. doi: 10.1097/TP.0b013e31817753f7.
146 Elevated level of HSPA1L mRNA correlates with graft-versus-host disease.Transpl Immunol. 2015 Jun;32(3):188-94. doi: 10.1016/j.trim.2015.02.002. Epub 2015 Feb 11.
147 Silent IL2RG Gene Editing in Human Pluripotent Stem Cells.Mol Ther. 2016 Mar;24(3):582-91. doi: 10.1038/mt.2015.190. Epub 2015 Oct 7.
148 Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection.Exp Hematol. 1985 Dec;13(11):1201-10.
149 Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.Blood Adv. 2019 Nov 12;3(21):3351-3359. doi: 10.1182/bloodadvances.2019000236.
150 PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.Blood Adv. 2019 Feb 12;3(3):360-369. doi: 10.1182/bloodadvances.2018027748.
151 Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.Blood. 2009 Mar 5;113(10):2312-23. doi: 10.1182/blood-2008-04-153825. Epub 2008 Dec 12.
152 An advanced BLT-humanized mouse model for extended HIV-1 cure studies.AIDS. 2018 Jan 2;32(1):1-10. doi: 10.1097/QAD.0000000000001674.
153 Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.Arthritis Rheumatol. 2016 Aug;68(8):2003-15. doi: 10.1002/art.39658.
154 Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2013 Aug;19(8):1197-203. doi: 10.1016/j.bbmt.2013.05.020. Epub 2013 Jun 6.